MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R

Leuk Lymphoma. 2018 Feb;59(2):505-508. doi: 10.1080/10428194.2017.1339882. Epub 2017 Jun 22.

Affiliations

¹ a Myeloid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute , National Institutes of Health , Bethesda , MD , USA.
² b Lymphoid Malignancies Branch , Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.
³ c Laboratory of Pathology , Clinical Center, National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
⁴ d Biostatistics and Data Management Section , Office of the Clinical Director, Center for Cancer Research, National Cancer Institute , Bethesda , MD , USA.

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Doxorubicin / adverse effects
Doxorubicin / therapeutic use
Etoposide / adverse effects
Etoposide / therapeutic use
Gene Rearrangement*
Humans
Kaplan-Meier Estimate
Lymphoma, Large B-Cell, Diffuse / diagnosis
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / genetics*
Lymphoma, Large B-Cell, Diffuse / mortality
Prednisone / adverse effects
Prednisone / therapeutic use
Proto-Oncogene Proteins c-myc / genetics*
Rituximab / administration & dosage
Treatment Outcome
Vincristine / adverse effects
Vincristine / therapeutic use

Substances

Proto-Oncogene Proteins c-myc
Rituximab
Vincristine
Etoposide
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

EPOCH protocol

Grants and funding

Z01 SC000550-27/Intramural NIH HHS/United States